MN, a 29-year-old asthmatic, has been diagnosed with migraines for almost two years. She is missing up to 4-5 days of work each month. Her headache diary confirms she averages five migraines per month. She currently uses a triptan with good effect to abort her migraines. She is on a controller medication for her asthma and uses albuterol as a rescue inhaler at least once a month. In addition to continuing her headache diary, which of the following would benefit MN?

Migraine prophylaxis is indicated in patients who experience frequent attacks, significant functional impairment, or poor quality of life despite effective abortive therapy. Preventive medications aim to reduce the frequency, severity, and duration of migraine episodes. In patients with comorbid conditions such as asthma, medication selection must avoid agents that may worsen respiratory function. Individualized therapy is essential to balance efficacy with safety. Rationale: A. Referral for ergotamine-based infusions is not appropriate for long-term migraine prevention. Ergotamine therapies are primarily used for acute or refractory migraine attacks, not routine prophylaxis. Additionally, infusion therapy is reserved for severe, treatment-resistant cases and would not be first-line for a stable outpatient with controlled abortive response using triptans. B. Amitriptyline (Elavil) is an appropriate choice for migraine prevention in this patient. It is effective in reducing migraine frequency by modulating serotonin and norepinephrine pathways involved in pain transmission. It is also safe in patients with asthma, unlike beta-blockers, making it a suitable prophylactic option for MN’s clinical profile. C. Propranolol (Inderal) is commonly used for migraine prophylaxis but should be avoided in patients with asthma. As a non-selective beta-blocker, it can cause bronchoconstriction by blocking beta-2 receptors in the lungs, potentially worsening asthma symptoms. Therefore, it is contraindicated in this patient despite its effectiveness for migraines. D. Phenytoin (Dilantin) is not indicated for migraine prophylaxis. It is primarily used for seizure disorders and has no established role in preventing migraines. Its adverse effect profile, including gingival hyperplasia and neurologic toxicity, makes it inappropriate for this clinical scenario.